| Literature DB >> 22238554 |
Matthias D'hooghe1, Stéphanie Vandekerckhove, Karen Mollet, Karel Vervisch, Stijn Dekeukeleire, Liesbeth Lehoucq, Carmen Lategan, Peter J Smith, Kelly Chibale, Norbert De Kimpe.
Abstract
A variety of 2-amino-3-arylpropan-1-ols, anti-2-amino-3-aryl-3-methoxypropan-1-ols and anti-2-amino-1-arylpropan-1,3-diols were prepared selectively through elaboration of trans-4-aryl-3-chloro-β-lactams. In addition, a number of 2-(azidomethyl)aziridines was converted into novel 2-[(1,2,3-triazol-1-yl)methyl]aziridines by Cu(I)-catalyzed azide-alkyne cycloaddition, followed by microwave-assisted, regioselective ring opening by dialkylamine towards 1-(2,3-diaminopropyl)-1,2,3-triazoles. Although most of these compounds exhibited weak antiplasmodial activity, six representatives showed moderate antiplasmodial activity against both a chloroquine-sensitive and a chloroquine-resistant strain of Plasmodium falciparum with IC(50)-values of ≤25 μM.Entities:
Keywords: aminopropanes; antimalarial activity; aziridines; ring opening; β-lactams
Year: 2011 PMID: 22238554 PMCID: PMC3252880 DOI: 10.3762/bjoc.7.205
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Figure 1Functionalized aminopropanes as potential antimalarial agents.
Scheme 1Synthesis of aminopropanols 6, 8 and 9.
Scheme 2Synthesis of syn-aminopropan-1,3-diols 12.
Scheme 3Synthesis of 2-[(1,2,3-triazol-1-yl)methyl]aziridines 15 and their transformation into 1,2,3-triaminopropanes 16.
IC50-values of compounds 6, 8, 9, 12, 14, 15 and 16 tested for in vitro antiplasmodial activity and cytotoxicity.
| Compound | R1 | R2 | R3 | D10: | Dd2: | CHO: | RIa | SIb |
| 4-Cl | Bn | – | 12.58 | 10.88 | 137.90 | 0.9 | 11 | |
| 4-OMe | iBu | – | 281.58 | ND | ND | ND | ND | |
| 2-F | – | 217.34 | ND | ND | ND | ND | ||
| H | iPr | – | 369.70 | ND | ND | ND | ND | |
| H | Bn | – | 143.79 | ND | ND | ND | ND | |
| 4-Cl | Bn | – | 198.56 | ND | ND | ND | ND | |
| 4-OMe | iBu | – | 38.56 | 25.69 | >530 | 0.7 | ND | |
| 2-F | – | 38.54 | 21.92 | >530 | 0.6 | ND | ||
| 4-Cl | Bn | – | 25.22 | 8.47 | >530 | 0.3 | ND | |
| 2-Cl | Bn | – | 21.18 | 13.57 | >530 | 0.6 | ND | |
| 4-Me | Bn | – | 129.86 | ND | ND | ND | ND | |
| H | 4-ClBn | – | 80.68 | ND | ND | ND | ND | |
| OMe | – | – | 98.68 | ND | ND | ND | ND | |
| F | – | – | 60.46 | ND | ND | ND | ND | |
| H | – | – | 230.40 | 466.81 | >530 | 2 | ND | |
| 4-Cl | – | – | 100.82 | ND | ND | ND | ND | |
| 4-OMe | – | – | 160.50 | ND | ND | ND | ND | |
| 2-Cl | – | – | 93.68 | ND | ND | ND | ND | |
| 3-Cl | – | – | 179.86 | ND | ND | ND | ND | |
| H | H | – | 34.44 | 106.97 | >530 | 3.1 | ND | |
| 4-Cl | H | – | 41.32 | ND | ND | ND | ND | |
| 4-OMe | H | – | 25.69 | 55.65 | >530 | 2.2 | ND | |
| H | Me | – | 20.43 | 20.99 | >530 | 1 | ND | |
| H | OMe | – | 40.54 | ND | ND | ND | ND | |
| 2-Cl | H | – | 32.33 | 25.00 | >530 | 0.8 | ND | |
| H | H | Et | 22.09 | 231.47 | >530 | 10.5 | ND | |
| 4-Cl | H | Et | 25.86 | 176.40 | >530 | 6.8 | ND | |
| 4-OMe | H | Et | 139.61 | ND | ND | ND | ND | |
| H | Me | Et | 32.55 | ND | ND | ND | ND | |
| H | OMe | Et | 171.37 | ND | ND | ND | ND | |
| 2-Cl | H | Me | 11.33 | 13.03 | 181.83 | 1.2 | 16.1 | |
| H | H | Me | 69.58 | ND | ND | ND | ND | |
| CQ | 19.14 ng/mL | 75.56 ng/mL | 3.9 | |||||
| Emetine | 0.27 | |||||||
aRI (Resistance Index) = IC50 Dd2/IC50 D10; bSI (Selectivity Index) = IC50 CHO/IC50 D10; ND = not determined; n = number of data sets averaged. The more hydrophobic samples were added to the parasites as a suspension, meaning that for these samples the reported IC50-value might be an underestimation of the activity.